NXS's Principal Activity is the research, development and commercialisation of technologies which solve issues in human health caused by biofilms.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+2.36%|
|vs ASX 200 (1yr)||-11.06%|
|ASX Rank||568 of 2,295|
|Sector Rank||42 of 177|
Next Science Limited (NXS) is a medical technology with research, development and commercialisation of technologies which solve issues in human health caused by biofilms. The company is headquartered in Sydney, Australia and has a research and development centre in Florida, USA.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Mark Raymond Compton||Non-Executive Director,Non-Executive Chairman||Oct 2018||
Mr Mark Raymond Compton
Non-Executive Director,Non-Executive Chairman
Mr Compton is Lord Prior of the International Order of St John and Chairman of the Board of Trustees of St John International. He is also Chairman of St Luke's Care Limited and Chairman of Integrated Clinical Oncology Network Pty Ltd trading as Icon Cancer Centre. Mark has held range of CEO and managing director roles, including at St Luke's Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012). He is a member of People, Culture Committee.
|Mrs Aileen Stockburger||Non-Executive Director||Oct 2018||
Mrs Aileen Stockburger
Mrs Stockburger was the Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson's efforts to acquire Synthes. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also part of range of other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He is a Non-Executive Director of Microbot Medical Inc. She is a member of Risk Committee.
|Ms Gillian Maria Nairn||Company Secretary||Jun 2018|
|Mr Bruce Alan Hancox||Non-Executive Director||Oct 2017||
Mr Bruce Alan Hancox
Mr Hancox has over 35 years of corporate experience across commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and Chairman and served on the board of a number of their subsidiaries in New Zealand, Australia and the US. Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market. He is a Director of Walker Group Holdings Pty Limited. He is Chair of the Risk Committee.
|Mr Daniel (Dan) Spira||Non-Executive Director||Oct 2017||
Mr Daniel (Dan) Spira
Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM North America and was also Managing Director, Pacific region. Prior to that, Daniel spent over 15 years at Johnson & Johnson Inc in range of roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions. He is a Chair of People, Culture Committee.
|Ms Judith Mitchell||Managing Director||Oct 2017||
Ms Judith Mitchell
Ms Mitchell served as President of DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson, before which Judith was President of Asia Pacific for Synthes GmbH. Judith commenced her medical technology career at GE Medical Systems, where over 14 years, she held positions in sales, marketing and management. She also held a range of positions at Cochlear Limited in Product Development, Global Marketing and Education.
|Dustin Haines||Chief Commercial Officer||N/A|
|Jacqueline Butler||Chief Financial Officer||N/A|
|Jon Swanson||Chief Operating Officer||N/A|
|Matthew Myntti||Chief Technology Officer||N/A|
NXS directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|28/04/21||Daniel (Dan) Spira||Sell||+3,487||$1.71||($5,962)||As advised by the company|
|26/04/21||Daniel (Dan) Spira||Sell||+362,342||$1.57||($568,876)||As advised by the company|
|13/04/21||Daniel (Dan) Spira||Exercise||1,040,000||$0.55||$572,000||Exercise of options|
|13/04/21||Daniel (Dan) Spira||Buy||+1,040,000||$0.55||$572,000||Exercise of options|
|24/11/20||Bruce Hancox||Buy||+130,000||$1.149||$149,344||On-market trade|
|24/11/20||Judith Mitchell||Buy||+24,362||$1.14||$27,772||On-market trade|
|24/11/20||Judith Mitchell||Buy||+43,000||$1.14||$49,020||On-market trade|
|29/10/20||Judith Mitchell||Buy||+22,438||$1.155||$25,907||On-market trade|
|29/10/20||Judith Mitchell||Buy||+178,200||$1.155||$205,755||On-market trade|
|28/10/20||Bruce Hancox||Buy||+30,000||$1.16||$34,800||On-market trade|
|19/10/20||George Savvides||Buy||+24,876||$1.18||$29,353||Participation in share purchase plan|
|19/10/20||Mark Compton||Buy||+12,438||$1.18||$14,676||Participation in share purchase plan|
|19/10/20||Judith Mitchell||Buy||+12,438||$1.18||$14,676||Participation in share purchase plan|
|02/10/20||Bruce Hancox||Buy||+154,330||$1.24||$191,369||On-market trade|
|24/09/20||Bruce Hancox||Buy||+70,000||$1.24||$86,800||On-market trade|
|24/09/20||Bruce Hancox||Buy||+145,670||$1.206||$175,707||On-market trade|
|06/05/20||Aileen Stockburger||Issued||11,283||$1.99||$22,453||Director remuneration|
|06/05/20||Daniel (Dan) Spira||Issued||12,537||$1.99||$24,948||Director remuneration|
|19/12/19||Aileen Stockburger||Issued||7,977||$2.82||$22,495||Director remuneration|
|19/12/19||Dan Spira||Issued||8,865||$2.82||$24,999||Director remuneration|
|25/09/19||Dan Spira||Issued||27,864||$1.674||$46,644||Director remuneration|
|25/09/19||Aileen Stockburger||Issued||25,577||$1.661||$42,475||Director remuneration|
The current holdings of NXS directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Daniel (Dan) Spira||28/04/2021||723,437||N/A||260,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Langley Alexander Walker||19/02/2021||76,072,938||39.53|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|16-10-20||Langley Alexander Walker||562,438||42.15||39.53|
|16-10-20||Auckland Trust Company Limited||562,438||42.15||39.53|
|16-10-20||Walker Group Holdings Pty Limited||562,438||42.15||39.53|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.